This is a prospective observational phase IV study of a novel, replication-deficient smallpox vaccine that has been recently been approved by FDA. The purpose of this study is to determine if there are any abnormalities detected by electrocardiographic testing and/or blood tests within 35 days of receiving the second dose of smallpox vaccine either alone or co-administered with other vaccines that may/may not be suggestive of myopericarditis.

Start Date01 Mar 2029

Sponsor / Collaborator

Womack Army Medical Center

[+1]

NCT06844487

/ RecruitingPhase 3IIT

Phase 3, Randomised Maternal and Infant (From 4 to 24 Months of Age) Safety and Immunogenicity Trial of MVA-BN® Vaccine in the Democratic Republic of the Congo

This Phase 3 double-blinded, randomized study aims to evaluate the safety and immunogenicity of the two-dose MVA-BN mpox vaccine regimen, administered subcutaneously, in infants and children aged 4 to 24 months in the Democratic Republic of the Congo (DRC), a population at high risk of mpox infection and complications. The study will compare the safety and immunogenicity of a full-dose regimen versus a half-dose regimen in this population. A hierarchical testing strategy will be applied as follows: first, non-inferiority of the full-dose regimen in infants/children (4-24 months old) will be evaluated against the full-dose regimen in adults from the POX-MVA-045 study. If non-inferiority is demonstrated, the immunogenicity of the half dose in infants/children (4-24 months old) will subsequently be tested for non-inferiority vs the full dose in adult. The trial will be conducted in Boende, Tshuapa Province, DRC.
The trial plans to enroll 344 male and female infants/children, who will be randomized to receive two doses of the MVA-BN vaccine administered 28 days apart. Participants in Child Group 1 (N=172) will receive the standard vaccine dose (0.5 mL), while those in Child Group 2 (N=172) will receive half the standard dose (0.25 mL), with both groups following the same dosing schedule.
This study builds on positive safety and immunogenicity data from prior trials that support the use of the standard dose regimen in younger children. However, considering the developmental differences in the immune systems of infants and young children/adolescents, it aims to evaluate whether a half-dose regimen can provide similar immunogenicity while potentially reducing reactogenicity. The findings will offer valuable insights into the optimal dosing strategy for this age group, balancing safety and immunogenicity to inform future vaccination recommendations.

Start Date29 May 2025

Sponsor / Collaborator

University of Antwerp

[+4]

NCT06829238

/ RecruitingPhase 4IIT

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use (MET-IH)

This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. Participants will receive metformin or placebo and undergo immune system assessments, including vaccine response evaluations.

Start Date07 Apr 2025

Sponsor / Collaborator

The University of Alabama at Birmingham

[+1]

100 Clinical Results associated with Smallpox vaccine(Bavarian Nordic A/S)

100 Translational Medicine associated with Smallpox vaccine(Bavarian Nordic A/S)

100 Patents (Medical) associated with Smallpox vaccine(Bavarian Nordic A/S)

346

Literatures (Medical) associated with Smallpox vaccine(Bavarian Nordic A/S)

31 Dec 2025·Virulence

Mpox: Global epidemic situation and countermeasures

Review

Author: Luo, Yinghua ; Jin, Chenghao ; Hou, Wenshuang ; Tang, Yanjun ; Wu, Nan ; Liu, Yanzhi ; Quan, Quan

Mpox, is a zoonotic disease caused by the monkeypox virus and is primarily endemic to Africa. As countries gradually stop smallpox vaccination, resistance to the smallpox virus is declining, increasing the risk of infection with mpox and other viruses. On 14 August 2024, the World Health Organization announced that the spread of mpox constituted a public health emergency of international concern. Mpox's transmission routes and symptoms are complex and pose new challenges to global health. Several vaccines (such as ACAM2000, JYNNEOS, LC16m8, and genetically engineered vaccines) and antiviral drugs (such as tecovirimat, brincidofovir, cidofovir, and varicella immunoglobulin intravenous injection) have been developed and marketed to prevent and control this disease. This review aims to introduce the epidemic situation, epidemiological characteristics, physiological and pathological characteristics, and preventive measures for mpox in detail, to provide a scientific basis for the prevention and control of mpox viruses worldwide.

01 Jul 2025·LANCET INFECTIOUS DISEASES

Safety and effectiveness of MVA-BN vaccination against mpox in at-risk individuals in Germany (SEMVAc and TEMVAc): a combined prospective and retrospective cohort study

Article

BACKGROUND:

More than 115 000 cases of mpox have been confirmed since the onset of a global outbreak in 2022. In addition to global transmission of clade II monkeypox virus (MPXV), the recent spread of clade I has caused a Public Health Emergency of International Concern. The third-generation smallpox vaccine modified vaccinia Ankara-Bavarian Nordic (MVA-BN) was recommended for at-risk populations in 2022, despite a scarcity of data on safety and effectiveness against mpox.

METHODS:

We did a prospective, multicentre, observational study, enrolling men who have sex with men and transgender people aged 18 years or older with changing sexual partners in Germany (Safety and Effectiveness of MVA-BN Vaccination Against MPXV Infection [SEMVAc]) between July 7, 2022, and Dec 31, 2023, evaluating safety and reactogenicity of one and two doses of subcutaneous MVA-BN. Vaccine effectiveness was estimated using risk ratios from the Kaplan-Meier estimator in an emulated retrospective target trial (Emulated Target Trial for Effectiveness of MVA-BN Vaccination Against mpox Infection in At-risk Individuals [TEMVAc]) from 3027 vaccinated individuals matched (1:1) to 3027 unvaccinated controls. SEMVAc and TEMVAc were registered in the HMA-EMA Catalogue, EUPAS50093, and the German Clinical Trials Register, DRKS00029638, and are complete.

FINDINGS:

6459 individuals were prospectively enrolled in SEMVAc. Adverse reactions were infrequent (first dose: 0·35% [95% CI 0·20-0·60] and second dose: 0·14% [0·06-0·33]). Local reactions were more frequent after the first dose (70·2% [95% CI 68·5-71·8]) compared with the second dose (56·8% [54·6-59]), as were systemic reactions (first dose, 22·3% [95% CI 20·9-23·9]; second dose, 17·6% [15·9-19·4]). In TEMVAc, 16 mpox cases were reported in vaccinated individuals versus 32 cases in matched unvaccinated individuals (median follow-up 55 days [IQR 23-89]). Effectiveness by 14 days or later after one dose was 57·8% (95% CI 11·8 to 83·0) overall, 84·1% (42·0 to 100) in people without HIV, but 34·9% (-72·8 to 79·0) in people living with HIV. Breakthrough infections were associated with reduced symptoms, compared with infections in unvaccinated individuals.

INTERPRETATION:

MVA-BN vaccination was safe and well tolerated. One dose of MVA-BN offered protection against mpox but effectiveness was reduced in people living with HIV. Although randomised controlled trials remain the preferred approach for assessing vaccine efficacy, combining prospective and retrospective study designs can be valuable during dynamic public health emergencies.

FUNDING:

European Medicines Agency.

TRANSLATION:

For the German translation of the abstract see Supplementary Materials section.

01 Jun 2025·JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Awareness and willingness towards Mpox vaccination among men who have sex with men seeking HIV-related services

Article

Author: Wang, Pei-Yu ; Chen, Kai-Hsiang ; Lin, Chia-Yi ; Hung, Chih-Hao ; Lin, Chi-Ying ; Li, Shu-Yuan ; Luo, Yu-Zhen ; Hung, Chien-Ching ; Cheng, Chien-Yu ; Peng, An-Ting ; Chen, Yi-Chun ; Chen, Ling-Ya ; Chen, Yi-Ting ; Chen, Wei-Yen ; Sun, Hsin-Yun ; Liu, Wang-Da ; Wu, Pei-Ying ; Chang, Hsi-Yen

We conducted a multicenter, on-line questionnaire interview of 1576 men who have sex with men planning to undergo or having undergone 2-dose MVA-BN vaccination to investigate the risk for acquiring Mpox, Mpox-related knowledge, awareness and willingness of Mpox vaccination, and the vaccination status. Upon the questionnaire interview, 794 (64.3%) people with HIV and 239 (69.9%) people without HIV had completed full doses of MVA-BN vaccination. Participants engaged in high-risk sexual behavior within one year (aOR 1.57; 95% CI, 1.24-1.99) and having acquired sexually transmitted infections within a year (aOR, 1.97; 95% CI 1.41-2.76) were more likely, while those with education below university level (aOR, 0.55; 95% CI, 0.42-0.73) and lower knowledge level about Mpox transmission (aOR, 0.34; 95% CI, 0.26-0.45) were less likely to complete full doses of Mpox vaccination, suggesting that promoting health literacy by providing information, education and communication on Mpox may improve the willingness of Mpox vaccination.

283

News (Medical) associated with Smallpox vaccine(Bavarian Nordic A/S)

26 Jun 2025

·pipelinereview.com

Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women

COPENHAGEN, Denmark I June 26, 2025 I Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of the first of two clinical trials designed to support approval and use of the MVA-BN ® mpox/smallpox vaccine in vulnerable populations: infants under 2 years of age and pregnant and breastfeeding women The first participants have been vaccinated in a study ( NCT06844487 ), evaluating the safety and immunogenicity of MVA-BN in 344 infants aged 4-24 months. Recruitment has also started in a second study ( NCT06844500 ), which is planned to enrol 359 women (pregnant or breastfeeding), also to be evaluated for safety and immunogenicity of MVA-BN. Both studies are conducted in the Democratic Republic of Congo (DRC), the epicentre of the ongoing mpox outbreak, where infants and pregnant women remain highly vulnerable to mpox. Paul Chaplin, President & CEO of Bavarian Nordic , said: “ Through partnerships we have made significant advances already by expanding access to our mpox vaccine for children and adolescents. These new studies will fill the gap by providing important data about the use of MVA-BN in infants and pregnant women, and we applaud the study partners as well as the funding partners, EDCTP3 and CEPI for supporting this important work which could help support a label expansion for MVA-BN to include the most vulnerable populations. ” Both studies are part of the PregInPoxVac research project, led by the University of Antwerp and the University of Kinshasa. The project is further supported by partners in Kenya (ACE Research) and Italy (Penta Foundation), funded by the European Union Global Health EDCTP3, the Coalition for Epidemic Preparedness Innovations (CEPI), and Bavarian Nordic. In addition, Bavarian Nordic is sponsoring a trial of MVA-BN in children aged 2-11 years, which has received funding support from CEPI. Topline results from this trial ( NCT06549530 ) are anticipated in the third quarter of 2025. Once full results become available, these could potentially support regulatory approval of MVA-BN for younger children. About the mpox vaccine MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is the only non-replicating mpox vaccine approved in the U.S., Switzerland, Singapore and Mexico (marketed as JYNNEOS ® ), Canada (marketed as IMVAMUNE ® ), and the EU/EAA and United Kingdom (marketed as IMVANEX ® ). Originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure the supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines, MVA-BN has been indicated for use in the general population in individuals considered at risk for smallpox or mpox infection. About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com . SOURCE: Bavarian Nordic

VaccineDrug ApprovalClinical Study

18 Jun 2025

·www.globenewswire.com

Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million

COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of USD 160 million. Bavarian Nordic was awarded the PRV in February 2025, following the approval by the U.S. Food and Drug Administration of the chikungunya vaccine, VIMKUNYA™ for prevention of disease caused by chikungunya virus in people 12 years of age and older. Pursuant to a license agreement assumed upon acquisition of the chikungunya vaccine in 2023, National Institutes of Health (NIH) will receive 20% of the gross proceeds from the sale of the PRV. The proceeds will be recognized as other operating income and thus will not impact the guided revenue expectations for 2025. However, EBITDA will be positively impacted and any impact on the guided EBITDA margin of 26-30% for 2025 will be updated upon closing of the transaction. The transaction remains subject to customary closing conditions, including anti-trust review, which is expected to occur in the third quarter of 2025. Jefferies LLC acted as exclusive financial advisor to Bavarian Nordic on this transaction. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors:Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03 Company Announcement no. 18 / 2025 Attachment 2025-18-en

VaccineDrug ApprovalPriority Review

12 Jun 2025

·www.globenewswire.com

Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children

First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, Denmark, June 12, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a Phase 3 clinical study of its single-dose, virus-like particle (VLP) chikungunya vaccine, CHIKV VLP in children 2 to 11 years of age. This first trial of CHIKV VLP in a pediatric population aims to expand the target population for the vaccine, currently approved for persons 12 years of age and older in the US, EU and United Kingdom under the trade name VIMKUNYA®. The global, randomized, double-blind, placebo-controlled study (NCT07003984), sponsored by Bavarian Nordic, will evaluate the safety and immunogenicity of CHIK VLP vaccine in 720 children 2 to 11 years of age for two years. Primary results from the study are anticipated in the first half of 2028. Paul Chaplin, President & CEO of Bavarian Nordic, said: “Upon the successful approvals earlier this year of our chikungunya vaccine for persons aged 12 and older, we are pleased to initiate this Phase 3 study in children for whom there are currently no vaccines available to prevent against chikungunya. This study represents a significant part of our commitment to the further development of the vaccine to help ensure access for people of all ages.” About VIMKUNYA® Chikungunya vaccine (recombinant, adsorbed)VIMKUNYA (CHIKV VLP) is the first and only virus-like particle (VLP) vaccine for the prevention of chikungunya disease in individuals aged 12 years and above. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as 1 week after vaccination. VIMKUNYA is the only single-dose vaccine against chikungunya disease available in a prefilled syringe. VIMKUNYA does not contain viral genetic material and is therefore non-infectious and unable to cause disease, ensuring a broad range of people can benefit from vaccination. The vaccine was approved by the U.S. Food and Drug Administration (FDA) and the European Commission in February 20251,2 and the United Kingdom in May 20253. The US, EU and UK approvals of VIMKUNYA (CHIKV VLP vaccine) were all based on results from two phase 3 clinical trials which enrolled more than 3,500 healthy individuals 12 years of age and older. The studies met their primary endpoints, with results showing that 21 days after vaccination, the vaccine induced neutralizing antibodies in up to 97.8% of the vaccinated individuals, (97.8% in individuals 12 years to 64 and 87.3% in over 65-year-olds). The key secondary endpoint of seroresponse rate at day 8 post vaccination was 46.6% and 96.8% at day 15 in the 12–64-year-old population and 82.3% at day 15 for the over 65 population. The vaccine was well-tolerated and vaccine-related adverse events were mainly mild or moderate in nature. The most common side effects were pain at the injection site, fatigue, headache, and muscle pain4,5. About chikungunyaChikungunya is a mosquito-borne disease caused by the chikungunya virus (CHIKV). In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas, including many popular travel destinations, often causing large unpredictable outbreaks. Since its discovery, CHIKV has been identified in more than 110 countries, with evidence of transmission confirmed in more than 50 countries over the past five years6. Chikungunya typically presents with acute symptoms, including fever, rash, fatigue, headache, and often severe and incapacitating joint pain. Most patients recover within 1-2 weeks, but 30-40% of those affected may develop chronic arthritis that can last for months or even years7. In 2024, 620,000 cases of chikungunya and over 200 deaths were reported worldwide8. Recent data suggest that chikungunya is severely underreported and often misdiagnosed as dengue fever due to a similar symptom profile9. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors:Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03 1 Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older. https://www.bavarian-nordic.com/media/media/news.aspx?news=7053 2 Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older. https://www.bavarian-nordic.com/media/media/news.aspx?news=7056 3 Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom. https://www.bavarian-nordic.com/media/media/news.aspx?news=7132 4 Richardson JS, et al. Chikungunya Virus VLP Vaccine: Phase 3 Trial in Adolescents and Adults. medRxiv 2024.10.11.24315179. 5 Tindale LC, et al. Chikungunya Virus VLP Vaccine: Phase 3 Trial in Adults ≥65 Years of Age. medRxiv 2024.10.10.24315205. 6 Centers for Disease Control and Prevention. Areas at Risk for Chikungunya. https://www.cdc.gov/chikungunya/data-maps/index.html. 7 European Centre for Disease Prevention and Control. Chikungunya virus disease. https://www.ecdc.europa.eu/en/chikungunya-virus-disease. 8 European Centre for Disease Prevention and Control. Chikungunya virus disease case notification rate per 100 000 population, January 2024-December 2024. https://www.ecdc.europa.eu/en/publications-data/chikungunya-virus-disease-case-notification-rate-100-000-population-january-2024. 9 Ribas Freitas AR, Pinheiro Chagas AA, Siqueira AM, Pamplona de Góes Cavalcanti L. How much of the current serious arbovirus epidemic in Brazil is dengue and how much is chikungunya? Lancet Reg Health Am. 2024 Apr 30;34:100753. doi: 10.1016/j.lana.2024.100753. PMID: 38711542; PMCID: PMC11070701. Attachment 2025-06-12-en

Phase 3Drug ApprovalClinical ResultVaccine

100 Deals associated with Smallpox vaccine(Bavarian Nordic A/S)

External Link

KEGG	Wiki	ATC	Drug Bank
-	Smallpox vaccine(Bavarian Nordic A/S)	J07BX	DB15483

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Monkeypox	European Union	Bavarian Nordic A/S	31 Jul 2013
Monkeypox	Iceland	Bavarian Nordic A/S	31 Jul 2013
Monkeypox	Liechtenstein	Bavarian Nordic A/S	31 Jul 2013
Monkeypox	Norway	Bavarian Nordic A/S	31 Jul 2013
Smallpox	European Union	Bavarian Nordic A/S	31 Jul 2013
Smallpox	Iceland	Bavarian Nordic A/S	31 Jul 2013
Smallpox	Liechtenstein	Bavarian Nordic A/S	31 Jul 2013
Smallpox	Norway	Bavarian Nordic A/S	31 Jul 2013
Vaccinia	European Union	Bavarian Nordic A/S	31 Jul 2013
Vaccinia	Iceland	Bavarian Nordic A/S	31 Jul 2013
Vaccinia	Liechtenstein	Bavarian Nordic A/S	31 Jul 2013
Vaccinia	Norway	Bavarian Nordic A/S	31 Jul 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pregnancy	Phase 3	Republic of the Congo	Bavarian Nordic A/S	23 Jun 2025
Dermatitis, Atopic	Phase 2	United States	Bavarian Nordic A/S	01 Jul 2006
Dermatitis, Atopic	Phase 2	Mexico	Bavarian Nordic A/S	01 Jul 2006
HIV Infections	Phase 2	United States	Bavarian Nordic A/S	01 Jun 2006
HIV Infections	Phase 2	Puerto Rico	Bavarian Nordic A/S	01 Jun 2006
Rhinitis, Allergic, Seasonal	Phase 1	Germany	Bavarian Nordic A/S	01 Apr 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05512949 (NEWS) Manual	Phase 2	Monkeypox	229	MVA-BN (aged between 12 and 17 years)	chefgmmwno(evcrjtfrdw) = After two doses, antibody levels were found to be equivalent at day 43 to those in adults aged 18 to 50 years. uogsraoxns (dyalutperc ) View more	Positive	17 Oct 2024
Literature Manual	Not Applicable	Monkeypox	45	MVA-BN 2 doses	gqircypuum(uvypvconcg) = 2 doses: mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 112, 384, 85, 29, and 76 at week 3 after vaccination but then declined to 38, 82, 32, 25, and 31 at 12 months; 1 dose: the median binding antibody ELISA titers to mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 45, 90, 32, 31, and 28 at week 3 but then declined to 33, 43, 30, 25, and 28 at 12 months gcqjvexfuq (imimjkfrkt )	Negative	03 Oct 2024
				MVA-BN 1 doses
NCT05740982 (NEWS) Manual	Phase 2	Hemorrhagic Fever, Ebola	526	IMVANEX (adolescents 12-17 years of age)	wbbljjgfgb(zpniwihogt) = a similar safety profile between both age groups pzejnlsbpw (wakcwhurdu ) View more	Positive	19 Sep 2024
				IMVANEX (adults aged 18 years and older)
NCT05512949 (CTgov)	Phase 2	Monkeypox	229	MVA-BN (2 x 10^7 ID MVA-BN)	gjsxexvahb(gmgyecdmts) = weqplksqkt lhzptgcoli (crcceefecx, obsoiodnmi - ncmlxitldi) View more	-	09 Jan 2024
				MVA-BN (1 x 10^7 ID MVA-BN)	gjsxexvahb(gmgyecdmts) = srnckioltg lhzptgcoli (crcceefecx, cehbrkfvrb - ulqyhfplhu) View more
NCT03699124 (Pubmed) Manual	Phase 3	-	1,129	MVA-BN	edzelmqwrs(gswwmqemxi) = pcizddtftl rdxnshuwea (uuxeooaxho ) View more	Positive	29 Nov 2022
NCT03699124 (CTgov)	Phase 3	Smallpox	1,129	FD MVA-BN (GP 1: Two Doses of FD MVA-BN--Lot 1)	zijrmulljh(vyaofuklfm) = upsmrgszve qiedaxiuzk (lfjuuhusao, vkpgphswbl - izxsvamehn) View more	-	27 May 2021
				FD MVA-BN (GP 2: Two Doses of FD MVA-BN--Lot 2)	zijrmulljh(vyaofuklfm) = boiikrfduv qiedaxiuzk (lfjuuhusao, pzyqqdctvv - lhytejkeeg) View more
NCT01668537 (CTgov)	Phase 2	Smallpox	651	LF (LF Formulation)	utontdbwko(nmufadussa) = hszebdlewn hfbslajgdz (fjbcdouoyk, vgmlpoipjj - uizijwtmor) View more	-	12 Oct 2020
				MVA-BN (FD Formulation)	utontdbwko(nmufadussa) = gykbhsbozt hfbslajgdz (fjbcdouoyk, rfcqqalnvc - uagvqdymyo) View more
NCT03472014 (CTgov)	Phase 4	-	22	MVA-BN	iciuiipmbr = eyfjwnbhco bdbftniied (odcgwzrcgz, jtaehrcuqa - jgkjquqnbr) View more	-	19 Aug 2020
NCT01913353 (Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 3	Smallpox	433	modified vaccinia Ankara+ACAM2000	iblgkpirru(dlhailgbkt): RO = 97.9 (95% CI, 96.6 - 98.3) View more	Superior	14 Nov 2019
				ACAM2000
NCT00686582 (CTgov)	Phase 2	Smallpox	304	IMVAMUNE (Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose)	gorxuboltn = zgzoihfouw adriydozgm (bwlmnpzfkw, qaozktimnj - wrloyzpdee) View more	-	18 Feb 2019
				IMVAMUNE (Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose)	gorxuboltn = abhcfpebld adriydozgm (bwlmnpzfkw, vnywtsuens - flyfppnpwi) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Smallpox vaccine(Bavarian Nordic A/S)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation